Literature DB >> 25725991

IL-25 as a novel therapeutic target in nasal polyps of patients with chronic rhinosinusitis.

Hyun-Woo Shin1, Dong-Kyu Kim2, Min-Hyun Park3, Kyoung Mi Eun3, Mingyu Lee4, Daeho So4, Il Gyu Kong5, Ji-Hun Mo6, Min-Suk Yang7, Hong Ryul Jin3, Jong-Wan Park4, Dae Woo Kim8.   

Abstract

BACKGROUND: Chronic rhinosinusitis (CRS) with nasal polyps (NPs) in Western populations is associated with TH2 cytokine polarization. IL-25, an IL-17 family cytokine, was recently reported to induce TH2-type immune responses and to contribute to several allergic diseases, such as atopic dermatitis and asthma. However, the role of IL-25 in Asian patients with nasal polyposis remains unclear.
OBJECTIVE: We sought to determine the role of IL-25 in Asian patients with nasal polyposis and CRS.
METHODS: We investigated IL-25 expression and its cellular origins in NPs of human subjects using immunohistochemistry (IHC), quantitative RT-PCR, and ELISA of NP tissues. Correlations between IL-25 expression and expression of other inflammatory markers in NP tissues were also explored. Anti-IL-25 neutralizing antibody was administered in an ovalbumin- and staphylococcal enterotoxin B-induced murine NP model to confirm the function of IL-25 during nasal polypogenesis.
RESULTS: IL-25 expression was upregulated in NP mucosa from patients with CRS with NPs compared with uncinate process tissue from control subjects and those with CRS without NPs. Overexpression of epithelial IL-25 was confirmed by using IHC, and double IHC staining showed that tryptase-positive cells were one of the main sources of IL-25 among immune cells. Furthermore, IL-17 receptor B levels were also increased in immune cells of patients with NPs compared with those in control subjects. In NPs IL-25 mRNA expression positively correlated with the expression of several inflammatory markers, including T-box transcription factor, RAR-related orphan receptor C, GATA3, eosinophil cationic protein, TGF-β1, and TGF-β2. IL-25 was more abundant in the murine NP model compared with control mice, and similar correlations between IL-25 and inflammatory markers were observed in murine models. Anti-IL-25 treatment reduced the number of polyps, mucosal edema thickness, collagen deposition, and infiltration of inflammatory cells, such as eosinophils and neutrophils. This treatment also inhibited expression of local inflammatory cytokines, such as IL-4 and IFN-γ. Furthermore, expression of CCL11, CXCL2, intercellular adhesion molecule 1, and vascular cell adhesion molecule 1 in the nasal mucosa was suppressed in the anti-IL-25-treated group.
CONCLUSION: Our results suggest that IL-25 secreted from the sinonasal epithelia and infiltrating mast cells plays a crucial role in the pathogenesis of CRS with NPs in Asian patients. In addition, our results suggest the novel possibility of treating nasal polyposis with anti-IL-25 therapy.
Copyright © 2015 American Academy of Allergy, Asthma & Immunology. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  IL-25; Nasal polyp; allergy; animal models; sinusitis

Mesh:

Substances:

Year:  2015        PMID: 25725991     DOI: 10.1016/j.jaci.2015.01.003

Source DB:  PubMed          Journal:  J Allergy Clin Immunol        ISSN: 0091-6749            Impact factor:   10.793


  56 in total

Review 1.  Is there a future for biologics in the management of chronic rhinosinusitis?

Authors:  Kent Lam; Robert C Kern; Amber Luong
Journal:  Int Forum Allergy Rhinol       Date:  2016-04-22       Impact factor: 3.858

Review 2.  The use of biologics for immune modulation in allergic disease.

Authors:  Willem van de Veen; Mübeccel Akdis
Journal:  J Clin Invest       Date:  2019-03-18       Impact factor: 14.808

3.  Increased TSLP, IL-33, IL-25, IL-19, IL 21 and amphiregulin (AREG) levels in chronic rhinosinusitis with nasal polyp.

Authors:  Murat Dogan; Mustafa Sahin; Cigdem Yenisey
Journal:  Eur Arch Otorhinolaryngol       Date:  2019-03-19       Impact factor: 2.503

Review 4.  Sentinels at the wall: epithelial-derived cytokines serve as triggers of upper airway type 2 inflammation.

Authors:  Neil N Patel; Michael A Kohanski; Ivy W Maina; Alan D Workman; De'Broski R Herbert; Noam A Cohen
Journal:  Int Forum Allergy Rhinol       Date:  2018-09-10       Impact factor: 3.858

5.  The role of IL-25 and IL-33 in chronic rhinosinusitis with or without nasal polyps.

Authors:  Atakan Ozturan; Hulya Eyigor; Mete Eyigor; Ustun Osma; Mustafa Deniz Yilmaz; Omer Tarik Selcuk; Levent Renda; Meral Gultekin
Journal:  Eur Arch Otorhinolaryngol       Date:  2016-08-13       Impact factor: 2.503

Review 6.  Contribution of Epithelial Cell Dysfunction to the Pathogenesis of Chronic Rhinosinusitis with Nasal Polyps.

Authors:  Michael Wynne; Carl Atkinson; Rodney J Schlosser; Jennifer K Mulligan
Journal:  Am J Rhinol Allergy       Date:  2019-08-05       Impact factor: 2.467

Review 7.  IL-25/IL-33/TSLP contributes to idiopathic pulmonary fibrosis: Do alveolar epithelial cells and (myo)fibroblasts matter?

Authors:  Xuefeng Xu; Jinglan Zhang; Huaping Dai
Journal:  Exp Biol Med (Maywood)       Date:  2020-04-04

8.  Development of a mouse model of eosinophilic chronic rhinosinusitis with nasal polyp by nasal instillation of an Aspergillus protease and ovalbumin.

Authors:  Ho Chan Kim; Ji Youn Lim; Seoyeon Kim; Ji Heui Kim; Yong Ju Jang
Journal:  Eur Arch Otorhinolaryngol       Date:  2017-08-21       Impact factor: 2.503

Review 9.  Biomarkers in the evaluation and management of chronic rhinosinusitis with nasal polyposis.

Authors:  Yao Yao; Shumin Xie; Chunguang Yang; Jianhui Zhang; Xuewen Wu; Hong Sun
Journal:  Eur Arch Otorhinolaryngol       Date:  2017-04-01       Impact factor: 2.503

10.  Solitary chemosensory cells producing interleukin-25 and group-2 innate lymphoid cells are enriched in chronic rhinosinusitis with nasal polyps.

Authors:  Neil N Patel; Michael A Kohanski; Ivy W Maina; Vasiliki Triantafillou; Alan D Workman; Charles C L Tong; Edward C Kuan; John V Bosso; Nithin D Adappa; James N Palmer; De'Broski R Herbert; Noam A Cohen
Journal:  Int Forum Allergy Rhinol       Date:  2018-05-09       Impact factor: 3.858

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.